Immunocore Holdings plc (IMCR) Operating Margin
- Operating margin · 12 months: Value -5.24%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -5.24% | Operating income / revenue. Period ending 2026-06-30. $-22.58M ÷ $430.77M × 100 ≈ -5.24% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -22.58M USD | Operating Income (Loss) |
| Revenue | 430.77M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 284.45M USD | Research and Development Expense |
| Selling, general and administration | 164.16M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-22.58M | $430.77M | (m) | $284.45M | $164.16M | -5.24% |
| 2026-03-31 | $-34.46M | $412.81M | (m) | $279.51M | $163.06M | -8.35% |
| 2025-12-31 | $-45.35M | $400.02M | (m) | $274.87M | $165.41M | -11.34% |
| 2025-09-30 | $-45.11M | $379.59M | (m) | $256.90M | $165.09M | -11.88% |
| 2025-06-30 | $-46.45M | $356.14M | (m) | $239.10M | $160.84M | -13.04% |
| 2025-03-31 | $-47.59M | $333.58M | (m) | $221.16M | $156.69M | -14.27% |
| 2024-12-31 | $-70.46M | $310.20M | (m) | $222.15M | $155.78M | -22.71% |
| 2024-09-30 | $-68.06M | $285.62M | (m) | $206.87M | $154.91M | -23.83% |
| 2024-06-30 | $-73.70M | $270.22M | (m) | $197.35M | $154.84M | -27.28% |
| 2024-03-31 | $-71.44M | $254.58M | (m) | $184.43M | $151.22M | -28.06% |
| 2023-12-31 | $-59.65M | $238.74M | (m) | $163.54M | $144.50M | -24.99% |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-51.71M | $140.69M | (m) | $101.92M | $123.06M | -36.75% |
| 2021-12-31 | $-174.59M | $4.08M | (m) | $100.25M | $110.82M | -4281.19% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |